Pharming Group N.V. (0QCO.IL)

0.9065 +0.0117 (+1.31%) At close: 05:39PM BST

Pharming Group N.V.

Darwinweg 24
Leiden 2333 CR
Netherlands
31 71 524 7400
https://www.pharming.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 332

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Sijmen de Vries M.B.A., M.D.	Pres, CEO & Exec. Director	1.18M	N/A	1959
Mr. Jeroen Wakkerman	Chief Financial Officer	N/A	N/A	1969
Ms. Mireille Sanders M.Sc.	Chief Operations Officer	N/A	N/A	1968
Susanne Embleton	Investor Relations Mang.	N/A	N/A	N/A
Mr. Ruud Van Outersterp	Chief Ethics & Compliance Officer	N/A	N/A	1964
Dr. Anurag Relan M.D., MPH	Chief Medical Officer	N/A	N/A	1972
Mr. Stephen Toor	Chief Commercial Officer & GM Americas	N/A	N/A	1971
Dr. Alexander Breidenbach M.B.A.	Chief Bus. Officer	N/A	N/A	N/A
Dr. Bruno M. L. Giannetti	Consultant	N/A	N/A	1952

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Corporate governance

Pharming Group N.V.’s ISS governance QualityScore as of 1 October 2023 is 4. The pillar scores are Audit: 7; Board: 1; Shareholder rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.